Inhibition of the epigenetic suppressor EZH2 primes osteogenic differentiation mediated by BMP2

• Published in: The Journal of biological chemistry Vol. 295; no. 23; pp. 7877 - 7893
• Main Authors: Dudakovic, Amel, Samsonraj, Rebekah M., Paradise, Christopher R., Galeano-Garces, Catalina, Mol, Merel O., Galeano-Garces, Daniela, Zan, Pengfei, Galvan, M. Lizeth, Hevesi, Mario, Pichurin, Oksana, Thaler, Roman, Begun, Dana L., Kloen, Peter, Karperien, Marcel, Larson, A. Noelle, Westendorf, Jennifer J., Cool, Simon M., van Wijnen, Andre J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05-06-2020; American Society for Biochemistry and Molecular Biology
• Subjects: 3T3 Cells; Animals; BMP2; bone development; bone morphogenetic protein (BMP); Bone Morphogenetic Protein 2 - administration & dosage; Bone Morphogenetic Protein 2 - metabolism; Cell Differentiation - drug effects; Cells, Cultured; chromatin regulation; enhancer of zeste homolog; Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors; Enhancer of Zeste Homolog 2 Protein - metabolism; epigenetics; Ezh2; Gene Regulation; histone methylation; Humans; Indoles - administration & dosage; Indoles - pharmacology; mesenchymal stem cells (MSCs); methyltransferase; Mice; osteoblast; Osteoblasts - drug effects; osteogenesis; Osteogenesis - drug effects; Pyridones - administration & dosage; Pyridones - pharmacology; histone methylation; BMP2; methyltransferase; mesenchymal stem cells (MSCs); chromatin regulation; enhancer of zeste homolog; bone development; bone morphogenetic protein (BMP); osteoblast; osteogenesis; epigenetics; Ezh2
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA119.011685

Bone-stimulatory therapeutics include bone morphogenetic proteins (e.g. BMP2), parathyroid hormone, and antibody-based suppression of WNT antagonists. Inhibition of the epigenetic enzyme enhancer of zeste homolog 2 (EZH2) is both bone anabolic and osteoprotective. EZH2 inhibition stimulates key components of bone-stimulatory signaling pathways, including the BMP2 signaling cascade. Because of high costs and adverse effects associated with BMP2 use, here we investigated whether BMP2 dosing can be reduced by co-treatment with EZH2 inhibitors. Co-administration of BMP2 with the EZH2 inhibitor GSK126 enhanced differentiation of murine (MC3T3) osteoblasts, reflected by increased alkaline phosphatase activity, Alizarin Red staining, and expression of bone-related marker genes (e.g. Bglap and Phospho1). Strikingly, co-treatment with BMP2 (10 ng/ml) and GSK126 (5 μm) was synergistic and was as effective as 50 ng/ml BMP2 at inducing MC3T3 osteoblastogenesis. Similarly, the BMP2–GSK126 co-treatment stimulated osteogenic differentiation of human bone marrow–derived mesenchymal stem/stromal cells, reflected by induction of key osteogenic markers (e.g. Osterix/SP7 and IBSP). A combination of BMP2 (300 ng local) and GSK126 (5 μg local and 5 days of 50 mg/kg systemic) yielded more consistent bone healing than single treatments with either compound in a mouse calvarial critical-sized defect model according to results from μCT, histomorphometry, and surgical grading of qualitative X-rays. We conclude that EZH2 inhibition facilitates BMP2-mediated induction of osteogenic differentiation of progenitor cells and maturation of committed osteoblasts. We propose that epigenetic priming, coupled with bone anabolic agents, enhances osteogenesis and could be leveraged in therapeutic strategies to improve bone mass.